ClinicalTrials.Veeva

Menu
V

Virginia Heart | Fairfax Office

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Apixaban
Bococizumab
sodium
BELVIQ
TQJ230
Finerenone
Milvexian
Inclisiran
LY3819469
Ziltivekimab

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

10 of 24 total trials

A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis

The purpose of this study is to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) administered subcutaneously once monthly compar...

Enrolling
Aortic Stenosis
Drug: Matching placebo
Drug: Pelacarsen (TQJ230) 80mg
Locations recently updated

This study will be done to see if ziltivekimab can be used to treat people living with heart failure and inflammation. Participants will either get z...

Enrolling
Heart Failure
Drug: Placebo
Drug: Ziltivekimab
Locations recently updated

CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c...

Enrolling
Primary Prevention of Atherosclerotic Cardiovascular Disease
Drug: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
Drug: Placebo in 1.5ml

The main purpose of this study is to determine the efficacy and safety of LY3819469 in adults with elevated lipoprotein(a). The study will lasts abou...

Active, not recruiting
Lipoprotein Disorder
Drug: Placebo
Drug: LY3819469

The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major advers...

Enrolling
Acute Coronary Syndrome
Drug: Milvexian
Other: Placebo

The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardio...

Active, not recruiting
Type 2 Diabetes Mellitus
Drug: Tirzepatide
Drug: Dulaglutide

The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who hav...

Enrolling
Atherosclerotic Cardiovascular Disease (ASCVD)
Elevated Lp(a)
Drug: Lepodisiran Sodium
Drug: Placebo

CKJX839D12303 is a research study to determine if the study treatment, called inclisiran, in comparison to placebo taken in addition to statin medica...

Enrolling
Coronary Artery Disease
Drug: Inclisiran sodium 300 mg
Drug: Placebo

The primary objective of this study is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death (C...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Placebo
Drug: Olpasiran

This study will randomize patients recently discharged from the hospital with a confirmed diagnosis of type 1 acute myocardial infarction (Thygesen e...

Invitation-only
Acute Myocardial Infarction
Combination Product: Placebo
Combination Product: Selatogrel

Trial sponsors

Amgen logo
Lilly logo
Novartis logo
Abbott logo
Bayer logo
Pfizer logo
Boehringer Ingelheim logo
Boston Scientific logo
Bristol-Myers Squibb (BMS) logo
Eisai logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems